BR112015002085A2 - proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção - Google Patents

proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção

Info

Publication number
BR112015002085A2
BR112015002085A2 BR112015002085A BR112015002085A BR112015002085A2 BR 112015002085 A2 BR112015002085 A2 BR 112015002085A2 BR 112015002085 A BR112015002085 A BR 112015002085A BR 112015002085 A BR112015002085 A BR 112015002085A BR 112015002085 A2 BR112015002085 A2 BR 112015002085A2
Authority
BR
Brazil
Prior art keywords
protein
polynucleotide
vector
treatment
pharmaceutical composition
Prior art date
Application number
BR112015002085A
Other languages
English (en)
Portuguese (pt)
Inventor
Xu Daigen
Moessner Ekkehard
Fischer Jens
Jasmin Duerner Lydia
Umana Pablo
Hosse Ralf
Emrich Thomas
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015002085(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of BR112015002085A2 publication Critical patent/BR112015002085A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112015002085A 2012-08-08 2013-08-05 proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção BR112015002085A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12179709 2012-08-08
PCT/EP2013/066342 WO2014023673A1 (en) 2012-08-08 2013-08-05 Interleukin-10 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
BR112015002085A2 true BR112015002085A2 (pt) 2017-12-19

Family

ID=48917543

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002085A BR112015002085A2 (pt) 2012-08-08 2013-08-05 proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção

Country Status (22)

Country Link
US (2) US9346872B2 (enExample)
EP (1) EP2882774B1 (enExample)
JP (3) JP2015530983A (enExample)
KR (1) KR20150038012A (enExample)
CN (1) CN104540848B (enExample)
AR (1) AR092050A1 (enExample)
AU (1) AU2013301656A1 (enExample)
BR (1) BR112015002085A2 (enExample)
CA (1) CA2876285A1 (enExample)
CL (1) CL2014003605A1 (enExample)
CO (1) CO7151522A2 (enExample)
CR (1) CR20140565A (enExample)
EA (1) EA201500208A1 (enExample)
IL (1) IL236809A0 (enExample)
MA (1) MA20150232A1 (enExample)
MX (1) MX2015001675A (enExample)
PE (1) PE20150645A1 (enExample)
PH (1) PH12015500284A1 (enExample)
SG (1) SG11201408526SA (enExample)
TW (1) TW201418283A (enExample)
WO (1) WO2014023673A1 (enExample)
ZA (1) ZA201409304B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655616T3 (es) 2010-08-13 2018-02-20 Roche Glycart Ag Anticuerpos anti-FAP y procedimientos de uso
ES2694564T3 (es) 2011-02-10 2018-12-21 Roche Glycart Ag Polipéptidos de interleucina-2 mutantes
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
MX2016010174A (es) * 2014-02-06 2016-11-15 Hoffmann La Roche Proteinas de fusion de interleucina-10 y usos de las mismas.
US10993990B2 (en) * 2014-05-16 2021-05-04 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
SG10201802098UA (en) 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
LT3224275T (lt) 2014-11-14 2020-05-25 F. Hoffmann-La Roche Ag Antigeną surišančios molekulės, apimančios tnf šeimos ligando trimerą
US20160175458A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
CN109068658A (zh) * 2015-11-18 2018-12-21 杜克大学 用于治疗癌症的肿瘤浸润淋巴细胞
SG11201804259UA (en) * 2015-12-04 2018-06-28 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
AU2017241161B2 (en) 2016-03-31 2022-05-26 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP7084881B2 (ja) * 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
CN112142859A (zh) * 2017-05-22 2020-12-29 杭州博虎生物科技有限公司 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CN111094356B (zh) * 2017-09-25 2022-11-01 苏州丁孚靶点生物技术有限公司 一种蛋白质异二聚体及其用途
EP3688023B1 (en) * 2017-09-25 2025-08-27 Shihuida Pharmaceutical Group (Jilin) Co., Ltd. Methods and compositions for cancer treatment
JP2021530243A (ja) 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規ｉｌ−２１プロドラッグおよびそれを使用する方法
AU2019328575B2 (en) 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
CA3108949A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
WO2020108426A1 (zh) * 2018-11-26 2020-06-04 江苏恒瑞医药股份有限公司 一种人白细胞介素10变体及其衍生物
US11084857B2 (en) 2018-12-05 2021-08-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nsp-interleukin-10 proteins and uses thereof
US20220144911A1 (en) * 2019-02-01 2022-05-12 Uab Research Foundation Methods and compositions for il10 signaling antagonism
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
WO2020181235A1 (en) * 2019-03-06 2020-09-10 Deka Biosciences, Inc. Il-10 variant molecules and methods of treating inflammatory disease and oncology
CN111909276A (zh) * 2019-05-10 2020-11-10 复旦大学 一种融合蛋白及其用途
CN114207135A (zh) * 2019-06-11 2022-03-18 夏尔人类遗传性治疗公司 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021006604A1 (ko) * 2019-07-08 2021-01-14 주식회사 프로젠 신규 융합단백질 및 그의 용도
WO2021006603A1 (ko) * 2019-07-08 2021-01-14 주식회사 프로젠 신규 알러지 질환 치료용 약학적 조성물
KR20210006302A (ko) * 2019-07-08 2021-01-18 주식회사 프로젠 신규 il-10 변이체 단백질 및 그의 용도
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
NZ787541A (en) 2019-11-25 2025-10-31 Alkermes Inc Substituted macrocyclic compounds and related methods of treatment
EP4100426A1 (en) * 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
US12187763B2 (en) 2020-02-11 2025-01-07 Immunitybio, Inc. Chromatography resin and uses thereof
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
CN115667290A (zh) 2020-05-12 2023-01-31 再生元制药公司 新型il10激动剂及其使用方法
WO2021230705A1 (ko) * 2020-05-14 2021-11-18 주식회사 프로젠 신규 재조합 융합단백질 및 그의 용도
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
IL298608A (en) 2020-06-01 2023-01-01 Hcw Biologics Inc Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2022020324A1 (en) * 2020-07-20 2022-01-27 Viela Bio, Inc. Immunocytokines for treatment of autoimmune and inflammatory conditions
KR20230096959A (ko) 2020-07-20 2023-06-30 데카 바이오사이언시즈, 인크. Il-10을 포함하는 이중 시토카인 융합 단백질
TW202237631A (zh) * 2020-12-10 2022-10-01 俄羅斯聯邦商拜奧卡德聯合股份公司 用於啟動人類ＩＬ－１０Ｒａ受體的免疫細胞因數及其用途
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
KR20220099656A (ko) * 2021-01-07 2022-07-14 주식회사 프로젠 신규 il-10 변이체 융합단백질 생산용 세포주 및 그의 용도
WO2022165443A1 (en) * 2021-02-01 2022-08-04 AskGene Pharma, Inc. Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
CN119101170A (zh) * 2021-11-02 2024-12-10 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
JP2025508939A (ja) 2022-03-02 2025-04-10 イミュニティーバイオ インコーポレイテッド 膵臓癌の治療方法
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2024144336A1 (ko) * 2022-12-30 2024-07-04 주식회사 프로젠 신규 이중 특이성 융합단백질 및 그의 용도
WO2024146463A1 (zh) * 2023-01-03 2024-07-11 深圳先进技术研究院 分泌白介素-10的细菌
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186567A (en) 1977-04-18 1980-02-05 Hitachi Metals, Ltd. Ornament utilizing rare earth-cobalt magnet
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EA200802289A1 (ru) * 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
RU2486198C2 (ru) * 2007-10-30 2013-06-27 Филоджен С.П.А. Антиген, ассоциированный с ревматоидным артритом
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
ES2655616T3 (es) 2010-08-13 2018-02-20 Roche Glycart Ag Anticuerpos anti-FAP y procedimientos de uso
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX2016010174A (es) 2014-02-06 2016-11-15 Hoffmann La Roche Proteinas de fusion de interleucina-10 y usos de las mismas.

Also Published As

Publication number Publication date
CA2876285A1 (en) 2014-02-13
CN104540848A (zh) 2015-04-22
ZA201409304B (en) 2017-09-27
CO7151522A2 (es) 2014-12-29
EP2882774B1 (en) 2018-10-03
EP2882774A1 (en) 2015-06-17
AU2013301656A1 (en) 2015-01-15
JP6985232B2 (ja) 2021-12-22
WO2014023673A1 (en) 2014-02-13
PH12015500284A1 (en) 2015-04-27
SG11201408526SA (en) 2015-03-30
CR20140565A (es) 2015-02-12
US9346872B2 (en) 2016-05-24
AR092050A1 (es) 2015-03-18
MX2015001675A (es) 2015-04-10
TW201418283A (zh) 2014-05-16
EA201500208A1 (ru) 2015-07-30
CL2014003605A1 (es) 2015-04-06
US20160340413A1 (en) 2016-11-24
JP2019033755A (ja) 2019-03-07
KR20150038012A (ko) 2015-04-08
US20140044674A1 (en) 2014-02-13
PE20150645A1 (es) 2015-05-11
IL236809A0 (en) 2015-03-31
MA20150232A1 (fr) 2015-07-31
CN104540848B (zh) 2019-05-31
JP2021087426A (ja) 2021-06-10
JP2015530983A (ja) 2015-10-29
US10040843B2 (en) 2018-08-07
HK1209439A1 (en) 2016-04-01

Similar Documents

Publication Publication Date Title
BR112015002085A2 (pt) proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
BR112015002765A2 (pt) proteína de fusão, polinucleotídeo, vetor, célula hospedeira, métodos para produzir a proteína de fusão, de tratamento de uma doença em um indivíduo e para ativação seletiva in vitro ou in vivo de células reguladoras, composição farmacêutica, uso da proteína de fusão e invenção.
BR112014001855A2 (pt) construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BR112014021103A8 (pt) anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112015013410A2 (pt) método para biosintetizar um ou mais produtos e hospedeiro recombinante
BR112014032105A2 (pt) método para o tratamento de câncer
BR112015000437A2 (pt) imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
PT2986304T (pt) Composição farmacêutica, métodos para o tratamento e suas utilizações
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112015000441A2 (pt) imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
BR112014027166A2 (pt) anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
SI2729151T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe
PT2877168T (pt) Composição farmacêutica ou cosmética para tratamento da alopecia
BR112014028647A2 (pt) composições e métodos para modulação da expressão de bdnf
DK2891492T3 (da) Endoparasit kontrol middel
HRP20170928T1 (hr) Inhibitori kinurenin-3-monooksigenaze, farmaceutski pripravci, i postupci za njihovu upotrebu
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
HRP20181458T1 (hr) Protusmisleni polinukleotidi za induciranje preskakanja egzona i postupci liječenja distrofija
DK2914630T3 (da) Hidtil ukendte antigen-bindende proteiner og deres anvendelse som adresseringsprodukt til behandling af kræft
AP2015008599A0 (en) Pharmaceutical composition for treating headache, and preparation method thereof
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112014016744A2 (pt) polipeptídeo, composição farmacêutica e método para a produção de um ou mais polipeptídeos
BR112014016736A2 (pt) composto, composição farmacêutica, método para tratamento, uso de um composto e invenção

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements